CP.TO 1.15VRT -18.06NVDA -7.33TSM -15.23JPM -6.1ZST.TO 0.01HSAV.TO -0.03HSUV.U.TO 0.03
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.72
-0.00 (0.00%)
as of Sep 14, 2026, 8:00:00 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
DON'T BUY

Pfizer Inc(PFE)

Jan 24, 2023
Healthcare is weak at the start of each year. Pfizer chart shows lower lows and lower highs. Doesn't see a strong seasonal pattern for Pfizer now. Things pick up in May/June for healthcare.
Photo of Brooke ThackrayBrooke ThackrayUnlock Rating
$44.66

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jan 23, 2023
The drug space is a difficult one to be in so he doesn't own stocks in that space. It did a massive business with the vaccine. Now it will have to spend a lot of cash to make acquisitions since the base business for the big pharmaceuticals is flattening.
Photo of Lorne SteinbergLorne Steinberg
No
Unlock Rating
$44.98

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Pfizer Inc(PFE)

Jan 19, 2023
Stockchase Research Editor: Michael O'Reilly Following on its mRNA success with the COVID vaccine, PFE is advancing an RSV vaccine candidate that stimulated an immune response in pregnant women -- key to reduce RSV infection that impacts 125,000 infants in the US annually. The stock trades at only 9x earnings and 2.7x book. Recently reported earnings support a ROE of 35% and the company has been aggressively retiring debt. We recommend a stop-loss at $35, looking to achieve $55.50 -- upside potential over 22%. Yield 0% (Analysts’ price target is $55.49)
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$44.96

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Jan 18, 2023
It's been downgraded and shares have gone down. It's cheap enough now. Buy some now and buy more if the dividend rises back to 4% (at 3.6% now). Their pipeline looks promising.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$45.00

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 12, 2023
(A Top Pick Jan 12/22, Down 15%) 11x forward PE. Outperforming S&P since early 2021. Healthy drug pipeline. Still sees 30B USD in sales for Covid vaccines and treatment. Defensive and steady growth. Weak relative to market in January, an opportunity. Yield is 3.5%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$47.48

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 09, 2022
Monday they hold an analysts meeting to discuss their drug pipeline. Their biggest problem is that the street thinks there isn't much more to this company than its Covid franchise. Untrue! They've made enough acquisitions and invested in their pipeline to keep making new drugs.
Photo of Jim Cramer - Mad MoneyJim Cramer - Mad MoneyUnlock Rating
$51.72

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
HOLD

Pfizer Inc(PFE)

Nov 23, 2022
Sell PFE to buy MRK? Likes and owns them both. MRK is more in the immuno oncology and cancer space, whereas PFE is more diversified. Defensive and growth characteristics. MRK hit a new high today. PFE hasn't done as well, but has performed over the last 2 years. Own both for different reasons. May want to trim in early part of next cycle. Yield is 3.3%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$48.78

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 12, 2022
It has always been part of their health care portfolio. It is losing some lustre and interest created by Covid but is still a good health care company with a good dividend. He likes others as well, maybe a bit better.
Photo of Robert LauzonRobert Lauzon
Owned
Unlock Rating
$47.76

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Track your Stocks in your Watch List
HOLD

Pfizer Inc(PFE)

Sep 08, 2022
When you're looking at pharma companies, you want to see the breadth of drugs that are in the pipeline, and any blockbuster drugs in there. You're also looking for dividends. Yield is 3.4%.
Photo of Stan WongStan Wong
Owned
Unlock Rating
$46.79

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 01, 2022
PFE vs. JNJ Coin flip. Both are stable for the long run. PFE is slightly cheaper right now.
Photo of Jason MannJason Mann
Owned
Unlock Rating
$46.48

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
SELL

Pfizer Inc(PFE)

Aug 10, 2022
Always a wall of worry around drug pricing, but rarely does it have a large impact. He sold this name after record revenues from vaccine news. He likes AZN, which is getting approval after approval. Another one is LLY, focusing on its diabetes and weight loss drug.
Photo of Jamie Murray Jamie Murray
No
Unlock Rating
$49.52

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Jul 15, 2022
Healthcare is his biggest sector. HC is seeing the classic shift to defensives as inflation peaks. Also, HC trades at only 18x while utilities and staples trade at 21x, so it's the cheapest defensive. He owns Pfizer, UNH and Regeneron.
Photo of Jason Snipe, CIO, Odyssey Capital AdvisorsJason Snipe, CIO, Odyssey Capital Advisors
Owned
Unlock Rating
$51.75

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 21, 2022
The entire drug sector hasn't been investable since the 1990s, because governments control drug prices and patent expiries. Pfizer is struggling to replace drugs coming off patent, like their cholesterol drug. It's really tough. It's a defensive sector, so the drug companies will hold up better and offer dividend growth.
Photo of Lorne SteinbergLorne SteinbergUnlock Rating
$48.11

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
premiumPremium content

Unlock this Panic-proof Portfolio opinion with Stockchase Premium

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Pfizer Inc(PFE)

Jun 14, 2022
(A Top Pick Apr 19/22, Down 3.2%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with PFE has triggered its stop at $48. To remain disciplined we recommend covering the position at this time.
Photo of The Panic-Proof Portfolio (Stockchase Research)The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$47.70

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Jun 08, 2022
Results highly influenced by Covid vaccine. Earnings might be stagnant going forward. His choice is MRK, reasonable and sustainable multiple of 12x and very good dividend. MRK's major drug is patent-protected until at least 2026, plus great drugs in pipeline.
Photo of Gordon ReidGordon Reid
No
Unlock Rating
$53.65

Stock price when the opinion was issued

$27.72

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 136 to 150 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

BUG 4.44$44.48
GS -40.73$988.45
NFLX 2.92$80.32
DAL -0.11$79.8
DML.TO -0.16$4.03

Today's Top Picks

CP.TO 1.15$124.99
VRT -18.06$239
NVDA -7.33$210.96
TSM -15.23$418.01
JPM -6.1$350.13

Popular Articles

Latest Sell Signals

AVGO -17.27$344.72
APP 10.28$334.24
XRE.TO 0.05$15.73
ORCL -5.49$144.79
ORCL -5.49$144.79

Most Recent Experts

Liz Young, Head of investment strategy at SoFi

Liz Young, Head of investment strategy at SoFi

SoFi

Stephen Weiss, Founder, Short Hills Capital Partners

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Joe Terranova

Joe Terranova

Virtus Investment Partners

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica

You may also like